+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Antineoplastic Agents Market by Type (Alkylating & Alkylating-like Agents, Antimetabolites, Antitumor Antibiotics), Structure (Cell Cycle Phase Nonspecific Agents, Cell Cycle Phase Specific Agents), Indication, Application, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 191 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5887460
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antineoplastic Agents Market size was estimated at USD 130.95 billion in 2023, USD 143.82 billion in 2024, and is expected to grow at a CAGR of 10.33% to reach USD 260.71 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antineoplastic Agents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antineoplastic Agents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antineoplastic Agents Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Limited, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ipsen S.A., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi Group, Sino Biopharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Antineoplastic Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Alkylating & Alkylating-like Agents
    • Antimetabolites
    • Antitumor Antibiotics
    • Hormonal Agents
    • Miscellaneous Agents
    • Natural Alkaloids
  • Structure
    • Cell Cycle Phase Nonspecific Agents
    • Cell Cycle Phase Specific Agents
  • Indication
    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
  • Application
    • Biological Agents
    • Chemotherapeutic Agents
    • Personalized Medicine
  • End-User
    • Ambulatory Surgical Centers
    • Cancer Rehabilitation Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Antineoplastic Agents Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antineoplastic Agents Market?
  3. What are the technology trends and regulatory frameworks in the Antineoplastic Agents Market?
  4. What is the market share of the leading vendors in the Antineoplastic Agents Market?
  5. Which modes and strategic moves are suitable for entering the Antineoplastic Agents Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antineoplastic Agents Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of cancer disorders among population
5.1.1.2. Growing awareness of cancer diagnostics and treatments
5.1.1.3. Advancements in healthcare infrastructure and oncology research
5.1.2. Restraints
5.1.2.1. High costs associated with cancer treatments and antineoplastic agents
5.1.3. Opportunities
5.1.3.1. Government initiatives to reduce costs related to cancer drugs
5.1.3.2. Emergence of plant-derived anticancer agents
5.1.4. Challenges
5.1.4.1. Stringent regulatory approval processes for antineoplastic agents
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Antineoplastic Agents Market, by Type
6.1. Introduction
6.2. Alkylating & Alkylating-like Agents
6.3. Antimetabolites
6.4. Antitumor Antibiotics
6.5. Hormonal Agents
6.6. Miscellaneous Agents
6.7. Natural Alkaloids
7. Antineoplastic Agents Market, by Structure
7.1. Introduction
7.2. Cell Cycle Phase Nonspecific Agents
7.3. Cell Cycle Phase Specific Agents
8. Antineoplastic Agents Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Leukemia
8.5. Lung Cancer
8.6. Ovarian Cancer
8.7. Prostate Cancer
9. Antineoplastic Agents Market, by Application
9.1. Introduction
9.2. Biological Agents
9.3. Chemotherapeutic Agents
9.4. Personalized Medicine
10. Antineoplastic Agents Market, by End-User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Cancer Rehabilitation Centers
10.4. Hospitals & Clinics
11. Americas Antineoplastic Agents Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antineoplastic Agents Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antineoplastic Agents Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AstraZeneca PLC
15.1.2. Biogen Inc.
15.1.3. Bristol-Myers Squibb Company
15.1.4. Dr. Reddy’s Laboratories Limited
15.1.5. Fresenius Kabi AG
15.1.6. GlaxoSmithKline PLC
15.1.7. Hikma Pharmaceuticals PLC
15.1.8. Ipsen S.A.
15.1.9. Merck KGaA
15.1.10. Novartis AG
15.1.11. Pfizer Inc.
15.1.12. Sanofi Group
15.1.13. Sino Biopharmaceutical Co., Ltd.
15.1.14. Takeda Pharmaceutical Company Limited
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. ANTINEOPLASTIC AGENTS MARKET RESEARCH PROCESS
FIGURE 2. ANTINEOPLASTIC AGENTS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTINEOPLASTIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTINEOPLASTIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTINEOPLASTIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTINEOPLASTIC AGENTS MARKET DYNAMICS
FIGURE 7. ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. ANTINEOPLASTIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTINEOPLASTIC AGENTS MARKET SIZE, BY STRUCTURE, 2023 VS 2030 (%)
FIGURE 10. ANTINEOPLASTIC AGENTS MARKET SIZE, BY STRUCTURE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. ANTINEOPLASTIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ANTINEOPLASTIC AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. ANTINEOPLASTIC AGENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ANTINEOPLASTIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. ANTINEOPLASTIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ANTINEOPLASTIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTINEOPLASTIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ANTINEOPLASTIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. ANTINEOPLASTIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Dr. Reddy’s Laboratories Limited
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ipsen S.A.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Group
  • Sino Biopharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information